Reuters logo
5 个月前
BRIEF-Loxo Oncology reports acceptance of larotrectinib oral presentations at ASCO annual meeting
2017年4月5日 / 上午11点09分 / 5 个月前

BRIEF-Loxo Oncology reports acceptance of larotrectinib oral presentations at ASCO annual meeting

April 5 (Reuters) - Loxo Oncology Inc:

* Loxo Oncology announces acceptance of larotrectinib oral presentations at the American Society Of Clinical Oncology (asco) annual meeting Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below